Vanguard Fiduciary Trust
XLO icon

Vanguard Fiduciary Trust’s Xilio Therapeutics XLO Stock Holding History

Vanguard Fiduciary Trust’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216K Sell
22,594
-5,881
-21% -$49.1K ﹤0.01% 3546
2026
Q1 		$239K Buy
+28,475
New +$233K ﹤0.01% 3459

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust's XLO Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Xilio Therapeutics (XLO) stake by 21% in Q2 2026, selling an estimated $49.1K and leaving 22,594 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #3546.

Vanguard Fiduciary Trust first reported a position in XLO in Q1 2026 and has held it in 2 quarters since. The position peaked at $239K in Q1 2026. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Vanguard Fiduciary Trust held 22,594 shares of Xilio Therapeutics worth $216K as of Q2 2026.
  • Vanguard Fiduciary Trust sold 5,881 Xilio Therapeutics shares in Q2 2026, an estimated $49.1K.
  • Xilio Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3546 holding.
  • Vanguard Fiduciary Trust first reported a position in Xilio Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Xilio Therapeutics position peaked at $239K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.